SG&A at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s SG&A?
- Mirum Pharmaceuticals, Inc. (MIRM) reported SG&A of $96.33M in Q1 2026.
- How has Mirum Pharmaceuticals, Inc.'s SG&A changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s SG&A increased by 66.9% year-over-year, from $57.71M to $96.33M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s SG&A?
- Over 4 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s SG&A has grown at a 44.3% compound annual growth rate (CAGR), from $59.22M to $257.03M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.